It’s over: Eli Lilly shares tank after its huge gamble on Alzheimer’s drug solanezumab ends in failure
Eli Lilly’s monumental effort to prove once and for all that solanezumab could work in delaying Alzheimer’s has ended in total failure. The pharma giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
